A team of biologists and biomedical researchers at UC San Diego has developed a new method to determine if bacteria are susceptible to antibiotics within a few hours, an advance that could slow the appearance of drug resistance and allow doctors to more rapidly identify the appropriate treatment for patients with life threatening bacterial infections.
In a paper published online this week in the journal EBioMedicine, the scientists reported the development of a rapid susceptibility test for Staphylococcus aureus, a bacterium that causes some 60 percent of hospital-acquired infections and which has spread in communities, causing pneumonia and a variety of skin and tissue infections in both healthy and immune-compromised individuals.
The development is important, say biomedical scientists, because of the critical need for physicians to rapidly discriminate between drug resistant strains (commonly termed MRSA for methicillin-resistant S. aureus) and drug sensitive strains, since these infections can progress rapidly, especially MRSA strains with additional resistance to newer antibiotics designed to treat pathogens that are now appearing in hospitals.
According to the Centers for Disease Control and Prevention, antibiotic resistance causes two million illnesses and 23,000 deaths annually, costing the U.S. economy approximately $20-billion a year in direct health care costs and nearly eight million extra days in the hospital. Indeed, bacteria are evolving resistance to antibiotics much more quickly than global biomedical research efforts are delivering new drugs to market, leading to the appearance of infections caused by bacteria that are now resistant to every therapy.
Rapid antimicrobial susceptibility testing allows doctors to discriminate between infections caused by drug sensitive bacteria, which can be treated with safe and effective antibiotics developed in what scientists call the golden age of drug discovery (the mid-20th century) such as penicillin, and those caused by drug resistant bacteria, which might require newer antibiotics, such as daptomycin or cubicin. This approach will decrease the emergence of resistance by reserving the newest drugs for those infections where they are most needed.
The interdisciplinary team at UC San Diego was comprised of two infectious-disease specialists in the School of Medicine, Victor Nizet, MD, and George Sakoulas, MD; two biologists in the Division of Biological Sciences, Kit and Joe Pogliano; and Diana Quach, a bioengineering graduate student. The scientists applied a method previously developed in the Pogliano laboratories for drug discovery to antibiotic susceptibility testing.
“Previously we developed a microscopy-based method that performs an autopsy on bacterial cells that allows us to determine how each cell died, and we have shown that this method can identify new antibiotics and help understand how these antibiotics work,” said Kit Pogliano, a professor of biology at UC San Diego who headed the research team. “We tested to see if this method could be applied to antibiotic susceptibility testing. Surprisingly, we not only found that our method was able to accurately differentiate sensitive S. aureus strains from resistant MRSA strains, but that we were able to identify two subgroups of MRSA strains, one of which is susceptible to combinations of antibiotics that could be used in the hospital. We are excited by the accuracy and speed of this test, as well as by its unanticipated ability to identify these two types of MRSA infections, which would have been missed by other tests.”
Examining single cells has two key advantages over other testing methods, say the researchers. First, it is rapid, cutting days off the time for typical culture-based assays. It often takes days for a doctor to receive information on resistance, and this means that patients with life-threatening infections are often treated with the assumption that the infection is drug-resistant. Second, this method does not rely on having any detailed understanding of the bacterium causing the infection, or of the genes that convey resistance. This is particularly important in this case, since resistance to the drugs used to treat MRSA infections arise by several evolutionary pathways via different combinations of mutations, and it could also provide rapid treatment information for newly emerging bacterial pathogens, such as that which caused the infections transmitted by endoscopes.
“Regardless of the type of bacterium, a healthy and growing bacterium looks different from a dead bacterium, so whenever we detect a difference in how the cells look, we know that the bacterium is sensitive to the antibiotic we have applied. When we combine careful culture conditions, cutting edge imaging methods and a detailed quantitative analysis, we can turn this simple approach into a reliable test,” said Joe Pogliano, a professor of biology.
“Rapid and precise identification of antibiotic sensitivity patterns allows the most potent and effective drug to be administered,” said Nizet, a professor of pediatrics and pharmacy. “Equally important, more specific antibiotic therapy can help preserve the normal bacteria living in our gut microbiome that play an important role in our health and immune system function.”
The UC San Diego biologists say their new method has the potential to be applied to many different types of bacteria. “Our new method worked surprising well at rapidly detecting antibiotic resistant strains of S. aureus,” said Diana Quach, a graduate student and lead author on the study. “We are now optimizing it to provide a more accurate test for other types of antibiotic resistant bacteria, such as Pseudomonas aeruginosa.”
Read more: Biologists Develop Method for Antibiotic Susceptibility Testing
The Latest on: Antibiotic susceptibility testing
[google_news title=”” keyword=”Antibiotic susceptibility testing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antibiotic susceptibility testing
- Sweden's Q-linea Gets 510(k) for Automated Sepsis Test Systemon April 26, 2024 at 3:10 pm
The system can perform automated phenotypic antimicrobial susceptibility testing and minimum inhibitory concentration analysis in approximately 24 hours.
- Study: Antibiotic use in patients hospitalized with COVID-19 appears to have no beneficial effect on clinical outcomeson April 25, 2024 at 3:10 pm
Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being ...
- Artificial Intelligence Help Prevent Superbugson April 24, 2024 at 12:50 pm
AI successfully devised highly efficient antibiotic cycling strategies for treating multiple strains of E. coli, effectively thwarting drug resistance.
- New antibiotics aren’t being fully used, study findson April 23, 2024 at 2:02 pm
A new study shows that, despite having newer options for antibiotic-resistant infections, US clinicians are still frequently opting for less optimal older, generic antibiotics.
- OsteoRemedies® Obtains Expanded Indications for SPECTRUM® Dual Antibiotic Bone Cementon April 23, 2024 at 5:03 am
OsteoRemedies® LLC, an orthopedic company focused on providing simple solutions to complex disorders, has announced FDA clearance for expanded indications for the SPECTRUM® GV Bone Cement. The ...
- Use of the Plaque Assay for Testing the Antibiotic Susceptibility of Intracellular Bacteriaon April 22, 2024 at 4:59 pm
In this review, we have discussed the different approaches currently used for plaque assays as applied to fastidious bacteria. First described for rickettsiae, the plaque assay methods have been ...
- Sluggish uptake of new antibiotics threatens future development and supply for highly resistant infectionson April 19, 2024 at 6:14 am
innovation in pathogen-specific trials, regularly updated guidance, innovative patient-centered end points, and rapid susceptibility testing will be key to appropriate and optimal use of these new ...
- Sluggish uptake of new antibiotics threatens future development and supply for highly resistant infectionson April 18, 2024 at 5:00 pm
and rapid susceptibility testing will be key to appropriate and optimal use of these new antibiotics.
- SCOUT RECEIVES FUNDING FROM CARB-X TO DEVELOP A LOW-COST POINT-OF-CARE AND HOME DIAGNOSTIC FOR GONORRHEA AND CHLAMYDIAon April 18, 2024 at 5:00 am
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1 million to diagnostics and health tech company Scout to demonstrate proof-of-concept and ...
- Antimicrobial Susceptibility Test Market Outlook, Key Players, Share, Size, Overview, Growth, and Forecast 2024 to 2032on April 11, 2024 at 3:40 pm
The Antimicrobial Susceptibility Test (AST) Market is a crucial segment within the broader landscape of healthcare diagnostics, catering to the pressing need for effective antimicrobial stewardship ...
via Bing News